Attenuation of hemolysate-induced cerebrovascular endothelial cell injury and of production of endothelin-1 and big endothelin-1 by an endothelin-converting enzyme inhibitor

Surgical Neurology

Volumn 58, Issue 3-4, 2002, Pages 181-187

  Chang, Chih Zen ^a   Winardi, Daniel ^a   Lin, Chih Lung ^a   Kwan, Aij Lie ^a,b   Jeng, Arco Y ^c   Kassell, Neal F ^b   Howng, Shen Long ^a   Lee, Kevin S ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cell protection; Cerebral vasospasm; CGS 26303; Endothelin 1; ET 1; Hemoglobin; Subarachnoid hemorrhage

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; BIG ENDOTHELIN 1; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; BRAIN BLOOD VESSEL; CELL DAMAGE; CELL DENSITY; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HEMOLYSATE; IMMUNOREACTIVITY; NEUROPROTECTION; NONHUMAN; RADIOIMMUNOASSAY;

ANIMALS; ASPARTIC ENDOPEPTIDASES; CATTLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; METALLOENDOPEPTIDASES; PHOSPHONIC ACIDS; PROTEIN PRECURSORS; RABBITS; SUBARACHNOID HEMORRHAGE; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 0036763645     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(02)00824-8     Document Type: Article

References (51)

1. Ahn K., Beningo K., Olds G., Hupe D. The endothelin-converting enzyme from human umbilical vein is a membrane-bound metalloprotease similar to that from bovine aortic endothelial cells. Proc Natl Acad Sci USA. 89:1992;8606-8610.
2. Aoki T., Takenaka K., Suzuki S., Kassell N.F., Sagher O., Lee K.S. The role of hemolysate in the facilitation of oxyhemoglobin-induced contraction in rabbit basilar arteries. J Neurosurg. 81:1994;261-266.
3. Asano T., Ikega I., Satoh S. Endothelin a potential modulator of cerebral vasospasm. Eur J Pharmacol. 190:1990;365-372.
4. Asano T., Ikega I., Suzuki Y. Endothelin and the production of vasospasm in dogs. Biochem Biophys Res Commun. 159:1989;1345-1351.
5. Byrne J.V., Griffith T.M., Edwards D.H., Harrison T.J., Johnston K.R. Investigation of the vasoconstrictor action of subarachnoid hemoglobin in the pig cerebral circulation in vivo. Br J Pharmacol. 97:1989;667-674.
6. Caner H.H., Kwan A.L., Arthur A., Jeng A.Y., Lappe R.W., Kassell N.F., Lee K.S. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J Neurosurg. 85:1996;917-922.
7. A receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 52:1993;825-834.
8. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart. N Engl J Med. 325:1991;303-310.
9. Comair Y.G., Schipper H.M., Brem S. The prevention of oxyhemoglobin-induced endothelial and smooth muscle cytoskeletal injury by deferoxamine. Neurosurgery. 32:1993;58-65.
10. De Lombaert S., Ghai R.D., Jeng A.Y., Trapani A.J., Webb R.L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun. 204:1994;407-413.
11. Dorsch N. Cerebral arterial spasm a clinical review. Br J Neurosurg. 9:1995;403-412.
12. Douglas S.A., Gellai M., Ezekeil M., Ohlstein E.H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 12:1994;561-567.
13. Foley P.L., Kassell N.F., Hudson S.B., Lee K.S. Hemoglobin penetration in the wall of the rabbit basilar artery after subarachnoid hemorrhage and intracisternal hemoglobin injection. Acta Neurochir. 123:1993;82-86.
14. Foley P.L., Takenaka K., Kassell N.F., Lee K.S. Cytotoxic effects of bloody cerebrospinal fluid on cerebral endothelial cells in culture. J Neurosurg. 81:1994;87-92.
15. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 114:1995;925-930.
16. Fujiwara S., Kassell N.F., Sasaki T., Nakagomi T., Lehman R.M. Selective hemoglobin inhibitor of endothelium-dependent vasodilatation of rabbit basilar artery. J Neurosurg. 64:1986;445-452.
17. Heros R.C., Zervas N.T., Varsos V. Cerebral vasospasm after subarachnoid hemorrhage an update. Ann Neurol. 14:1983;599-608.
18. Hori T., Kashiyama S., Hayakawa M., Shibamoto S., Tsujimoto M., Oku N., Ito F. Tumor necrosis factor is cytotoxic to human fibroblasts in the presence of exogenous arachidonic acid. Exp Cell Res. 185:1989;41-49.
19. A receptor antagonist, BQ-485, and its preventative effect of experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun. 195:1993;969-975.
20. Kassell N.F., Sasaki T., Colohan A.R.T., Narzar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 16:1985;562-572.
21. Kwan A.L., Solenski N.J., Kassell N.F., Lee K.S. Hemolysate induces structural and functional injury to cultured cerebral endothelial cells. Kaohsiung J Med Sci. 13:1997;67-74.
22. Kwan A.L., Solenski N.J., Kassell N.F., Lee K.S. Inhibition of nitric oxide generation and lipid peroxidation attenuates hemolysate-induced injury to cerebrovascular endothelium. Acta Neurochir. 139:1997;240-248.
23. Kwan A.L., Bavbek M., Jeng A.Y., et al. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg. 87:1997;281-286.
24. Lewis P.J., Weir B.K., Nosko M.D., Tanabe T., Grace M.G. Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm. Neurosurgery. 22:1988;492-500.
25. Macdonald R.L., Weir B.K.A. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 22:1991;971-982.
26. Machi T., Kassell N.F., Scheld W.M. Isolation and characterization of endothelial cells from bovine cerebral arteries. In Vitro Cell Dev Biol. 26:1990;291-300.
27. Matsumura Y., Ikegawa R., Suzuki Y., et al. Phosphoramidon prevents cerebral vasospasm following subarachnoid haemorrhage in dogs the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci. 49:1991;841-848.
28. Mayberg M.R., Okada T., Bark D. The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg. 72:1990;626-633.
29. A receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci. 52:1993;1869-1874.
30. Nishikibe M., Tsuchida S., Okada M., et al. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 52:1993;717-724.
31. Ohlstein E.H., Nambi P., Douglas S.A., et al. SB 209670, a rationally designed potent non-peptide endothelin receptor antagonist. Proc Natl Acad Sci USA. 91:1994;8052-8056.
32. Ohta T., Satoh G., Kuriowa T. The permeability change of major cerebral arteries in experimental vasospasm. Neurosurgery. 30:1992;331-336.
33. Okada K., Miyazaki Y., Takada J., Matsuyama K., Yamaki T., Yano M. Conversion of big endothelin-1 by membrane-bound metalloendopeptidase in culture bovine endothelial cells. Biochem Biophys Res Commun. 171:1990;1192-1198.
34. Okwuasaba F., Cook D., Weir B. Change in vasoactive properties of blood products with time and attempted identification of the spasmogens. Stroke. 12:1981;775-780.
35. Opgenorth T.J., Wu-Wong J.R., Shiosaki K. Endothelin-converting enzymes. FASEB J. 6:1992;2653-2659.
36. Osaka K. Prolonged vasospasm produced by the breakdown products of erythrocytes. J Neurosurg. 47:1977;403-411.
37. Osaka K., Handa H., Okamoto S. Subarachnoid erythrocytes and their contribution to cerebral vasospasm. Wood J.H. Neurobiology of Cerebrospinal Fluid. 1980;313-323 Plenum Press, New York.
38. Ozaki N., Mullan S. Possible role of the erythrocyte in causing prolonged cerebral vasospasm. J Neurosurg. 51:1979;773-778.
39. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 22:(Suppl. 4):1993;S1-S14.
40. Rupnick M.A., Carey A., Williams S.K. Phenotypic diversity in cultured cerebral microvascular endothelial cells. In Vitro Cell Dev Biol. 24:1995;435-444.
41. Saito Y., Nakao K., Mukoyama M., et al. Application of monoclonal antibodies for endothelin to hypertensive research. Hypertension. 15:1990;734-738.
42. Schini V.B., Hendrickson H., Heublein D.M., Burnett C. Jr, Vanhoutte P.M. Thrombin enhances the release of endothelin from porcine aortic cells. Eur J Pharmacol. 165:1989;333-334.
43. Simonson M.S., Dunn M.J. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med. 119:1992;622-639.
44. Takenaka K., Kassell N.F., Foley P.L., Lee K.S. Oxyhemoglobin-induced cytotoxicity and arachidonic acid release in cultured bovine endothelial cells. Stroke. 24:1993;839-846.
45. Trapani A.J., De Lombaert S., Kuzmich S., Jeng A.Y. Inhibition of big ET-1 induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase. J Cardiovasc Pharmacol. 26:(Suppl. 3):1995;S69-S71.
46. Tsuji T., Weir B.K.A., Cook D.A. Time-dependent effects of extraluminally-applied oxyhemoglobin and endothelial removal on vasodilator responses in isolated, perfused canine basilar arteries. Pharmacology. 38:1989;101-112.
47. Weir B., Rothberg C., Grace M., Davis F. Relative prognostic significance of vasospasm following subarachnoid hemorrhage. Can J Neurol Sci. 2:1975;109-114.
48. Wellum G.R., Irvine T.W. Jr, Zervas N.T. Dose response of cerebral arteries of the dog, rabbit, and man to human hemoglobin in vitro. J Neurosurg. 53:1982;486-490.
49. Wollersheim H., van Zweiten P.A. Treatment of Raynaud's phenomenon. Eur Heart J. 14:1993;147-149.
50. Yamaura I., Tani E., Maeda Y., Minami N., Shindo H. Endothelin-1 of canine basilar artery in vasospasm. J Neurosurg. 76:1992;99-105.
51. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.